Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters


Database
Language
Year of publication
Document type
Publication year range
1.
Int J Antimicrob Agents ; 49(5): 554-557, 2017 May.
Article in English | MEDLINE | ID: mdl-28336312

ABSTRACT

Recently, multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic challenge. In addition to drug resistance, drug adverse events, intravenous delivery, cost and availability of some antibiotics in low-income countries have led to a look back to old drugs, especially those efficient against closely related organisms such as Mycobacterium leprae. Here we review the available drugs that respect the conditions above and could be upgraded to first-line therapy for treating MDR-TB and extensively drug-resistant tuberculosis (XDR-TB).


Subject(s)
Antitubercular Agents/therapeutic use , Drug Synergism , Extensively Drug-Resistant Tuberculosis/drug therapy , Mycobacterium tuberculosis/drug effects , Antitubercular Agents/adverse effects , Clarithromycin/adverse effects , Clarithromycin/therapeutic use , Clofazimine/adverse effects , Clofazimine/therapeutic use , Drug Resistance, Multiple, Bacterial , Extensively Drug-Resistant Tuberculosis/microbiology , Humans , Minocycline/adverse effects , Minocycline/therapeutic use , Phenothiazines/adverse effects , Phenothiazines/therapeutic use , Sulfonamides/adverse effects , Sulfonamides/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL